| Autor: |
Howard SR; Centre for Endocrinology, William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London, UK.; Department of Paediatric Endocrinology, Barts Health NHS Trust, London, UK., Freeston S; Whipps Cross Hospital, Barts Health NHS Trust, London, UK., Harrison B; Retired Endocrine Surgeon, Sheffield, UK., Izatt L; Department of Clinical and Cancer Genetics, Guy's and St Thomas' NHS Foundation Trust, London, UK., Natu S; Department of Pathology, University Hospital of North Tees and Hartlepool NHS Foundation Trust, Stockton-on-Tees, UK., Newbold K; Department of Clinical Oncology, Royal Marsden Hospital Foundation Trust, London, UK., Pomplun S; Department of Pathology, University College London Hospital NHS Foundation Trust, London, UK., Spoudeas HA; Department of Paediatric Endocrinology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK., Wilne S; Department of Paediatric Oncology, Nottingham University Hospital's NHS Trust, Nottingham, UK., Kurzawinski TR; Department of Endocrine Surgery, University College London Hospitals NHS Foundation Trust, London, UK.; Department of Paediatric Endocrine Surgery, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK., Gaze MN; Department of Clinical Oncology, University College London Hospitals NHS Foundation Trust, London, UK.; Department of Clinical Oncology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK. |
| Abstrakt: |
This guideline is written as a reference document for clinicians presented with the challenge of managing paediatric patients with differentiated thyroid carcinoma up to the age of 19 years. Care of paediatric patients with differentiated thyroid carcinoma differs in key aspects from that of adults, and there have been several recent developments in the care pathways for this condition; this guideline has sought to identify and attend to these areas. It addresses the presentation, clinical assessment, diagnosis, management (both surgical and medical), genetic counselling, follow-up and prognosis of affected patients. The guideline development group formed of a multi-disciplinary panel of sub-speciality experts carried out a systematic primary literature review and Delphi Consensus exercise. The guideline was developed in accordance with The Appraisal of Guidelines Research and Evaluation Instrument II criteria, with input from stakeholders including charities and patient groups. Based on scientific evidence and expert opinion, 58 recommendations have been collected to produce a clear, pragmatic set of management guidelines. It is intended as an evidence base for future optimal management and to improve the quality of clinical care of paediatric patients with differentiated thyroid carcinoma. |
